Gene therapy for glycogen storage diseases

Area of Science:

• Biomedical research
• Genetic medicine
• Metabolic disorders

Background:

• Glycogen storage diseases (GSDs) stem from enzyme deficiencies impacting glucose metabolism.
• GSDs affect various tissues, including the liver and muscles, with distinct subtypes like GSD Ia and GSD II.
• Limited therapeutic options necessitate the development of novel treatments for GSDs.

Purpose of the Study:

• To review the development of gene therapy for glycogen storage diseases (GSDs).
• To highlight the potential of gene therapy in addressing enzyme deficiencies in GSDs.
• To assess the progress of gene therapy from preclinical models to clinical trials for GSDs.

Main Methods:

• Utilizing adeno-associated virus (AAV) vectors for gene delivery.
• Targeting specific tissues like the liver, kidney, and muscle for enzyme replacement.
• Advancing gene therapy approaches through animal models and early-phase clinical trials.

Main Results:

• AAV vectors demonstrated effective tropism for target tissues in GSD animal models.
• Successful transduction of liver, kidney, and muscle tissues to restore enzyme function.
• Gene therapy for GSD Ia and GSD II has progressed to early clinical trials.

Conclusions:

• Gene therapy holds significant promise for treating various GSDs.
• Preclinical and clinical advancements indicate a hopeful future for GSD patients.
• Further research and clinical trials are expected to yield more effective therapies for GSDs.